🔎 Trials Near Me

Home › Kanser sa Baga › Oklahoma

Pag-aaral pangklinika para sa Kanser sa Baga sa Oklahoma

20 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa Oklahoma.

Mga Lungsod sa Oklahoma

Opisyal na teksto ng pag-aaral (English)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Cancer Centers of Southwest Oklahoma Research, Lawton
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04267848

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Integris Cancer Institute of Oklahoma, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04181060

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Mercy Hospital Oklahoma City, Oklahoma City
Nagre-recruitPhase 3
Edad 70 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06096844

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • University of Oklahoma, Oklahoma City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Oklahoma, Oklahoma City
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04585750

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

  • Site 101, Oklahoma City
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 30 hanggang 80 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06816121

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Oklahoma City, Oklahoma City
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069

The Vanguard Study: Testing a New Way to Screen for Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 45 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06995898

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06500481

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05624996

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Oklahoma City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05433142

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT05652686

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Cancer Centers of Southwest Oklahoma Research, Lawton
  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Cancer Centers of Southwest Oklahoma Research, Lawton
  • University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 2
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Cancer Centers of Southwest Oklahoma Research, Lawton
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Integris Southwest Medical Center, Oklahoma City
  • at 1 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Tulsa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Hightower Clinical, Oklahoma City
Nagre-recruitObservasyonal na pag-aaral
Edad 50 pataas · Lahat ng kasarian · Na-update Ago 5, 2025 · NCT06122077

Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.